期刊文献+

Extraction, detection, and profiling of serum biomarkers using designed Fe3O4@SiO2@HA core-shell particles 被引量:2

Extraction, detection, and profiling of serum biomarkers using designed Fe3O4@SiO2@HA core-shell particles
原文传递
导出
摘要 Serum biomarkers in the form of proteins (e.g. cluster of differentiation-44 (CD44)) have been demonstrated to have high clinical sensitivity and specificity for disease diagnosis and prognosis. Owing to the high sample complexity and low molecular abundance in serum, the detection and profiling of biomarkers rely on efficient extraction by materials and devices, mostly using immunoassays via antibody-antigen recognition. Antibody-free approaches are promising and need to be developed for real-case applications in serum to address the limitations of antibody-based techniques in terms of robustness, expense, and throughput. In this work, we demonstrated a novel approach using hyaluronic acid (HA)-modified materials/devices for the extraction, detection, and profiling of serum biomarkers via ligand-protein interactions. We constructed Fe304@SiOa@HA particles with different sizes through layer-by-layer assembly and for the first time applied HA-functionalized particles in the facile extraction and sequence identification of CD44 in serum by mass spectrometry. We also first validated HA-CD44 binding through electrochemical sensing using HA- modified electrodes in both standard solutions and diluted serum samples, achieving a detection limit of -0.6 ng/mL and a linear response range from I ng/mL to 10 ~tg/mL. Furthermore, we performed profiling of HA-binding serum proteome, providing a new preliminary benchmark for the construction of future databases, and we investigated selected surface chemistries of particles for the capture of proteins in serum. Our work not only resulted in the development of a platform technology for CD44 extraction/detection and HA-binding proteome identification, but also guided the design of ligand affinity-based approaches for antibody-free analysis of serum biomarkers towards diagnostic applications. Serum biomarkers in the form of proteins (e.g. cluster of differentiation-44 (CD44)) have been demonstrated to have high clinical sensitivity and specificity for disease diagnosis and prognosis. Owing to the high sample complexity and low molecular abundance in serum, the detection and profiling of biomarkers rely on efficient extraction by materials and devices, mostly using immunoassays via antibody-antigen recognition. Antibody-free approaches are promising and need to be developed for real-case applications in serum to address the limitations of antibody-based techniques in terms of robustness, expense, and throughput. In this work, we demonstrated a novel approach using hyaluronic acid (HA)-modified materials/devices for the extraction, detection, and profiling of serum biomarkers via ligand-protein interactions. We constructed Fe304@SiOa@HA particles with different sizes through layer-by-layer assembly and for the first time applied HA-functionalized particles in the facile extraction and sequence identification of CD44 in serum by mass spectrometry. We also first validated HA-CD44 binding through electrochemical sensing using HA- modified electrodes in both standard solutions and diluted serum samples, achieving a detection limit of -0.6 ng/mL and a linear response range from I ng/mL to 10 ~tg/mL. Furthermore, we performed profiling of HA-binding serum proteome, providing a new preliminary benchmark for the construction of future databases, and we investigated selected surface chemistries of particles for the capture of proteins in serum. Our work not only resulted in the development of a platform technology for CD44 extraction/detection and HA-binding proteome identification, but also guided the design of ligand affinity-based approaches for antibody-free analysis of serum biomarkers towards diagnostic applications.
出处 《Nano Research》 SCIE EI CAS CSCD 2018年第1期68-79,共12页 纳米研究(英文版)
关键词 ligand-protein interaction magnetic particles serum biomarkers cluster of differentiation44(CD44) sensors mass spectrometry ligand-protein interaction,magnetic particles,serum biomarkers,cluster of differentiation44(CD44),sensors,mass spectrometry
  • 相关文献

参考文献3

二级参考文献52

  • 1Leader, B.; Baca, Q. J.; Golan, D. E. Protein therapeutics: A summary and pharmacological classification. Nat. Rev. Drug Discov. 2008, 7, 21-39.
  • 2Krejsa, C.; Rogge, M.; Sadee, W. Protein therapeutics: New applications for pharmacogenetics. Nat. Rev. Drug Discov. 2006, 5, 507-521.
  • 3Christian, D. A.; Cai, S. S.; Bowen, D. M.; Kim, Y.; Pajerowski, J. D.; Diseher, D. E. Polymersome carriers: From self-assembly to siRNA and protein therapeutics. Eur. J. Pharm. Biopharm. 2009, 71,463-474.
  • 4Baker, M.; Reynolds, H. M.; Lumicisi, B.; Bryson, C. J. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self/Nonself2010, 1, 314-322.
  • 5Manning, M. C.; Chou, D. K.; Murphy, B. M.; Payne, R. W.; Katayama, D. S. Stability of protein pharmaceuticals: An update. Pharm. Res. 2010, 27, 544-575.
  • 6Manning, M. C.; Patel, K.; Borchardt, R. T. Stability of protein pharmaceuticals. Pharm. Res. 1989, 6, 903-918.
  • 7Alhanese, A.; Tang, P. S.; Chan, W. C. W. The effect of nanopartiele size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 2012, 14, 1-16.
  • 8Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001, 53, 283-318.
  • 9Pisal, D. S.; Kosloski, M. P.; Balu-Iyer, S. V. Delivery of therapeutic proteins. J. Pharm. Sci. 2010, 99, 2557-2575.
  • 10Harris, J. M.; Chess, R. B. Effect ofpegylation on pharma- ceuticals. Nat. Rev. Drug Discov. 2003, 2, 214-221.

共引文献25

同被引文献6

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部